Covered recipient · General Payments record
MICHELLE R VIEIRA
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2019–2025
$2,150.89
- Reported across 156 records
- CMS publication 2026-06-30
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2025 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $385.48 | 16 |
By paying entity
PY2025 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $121.74 | 1 |
| ABBVIE INC. | $55.95 | 3 |
| Supernus Pharmaceuticals, Inc. | $47.93 | 3 |
| Ardelyx, Inc. | $37.29 | 2 |
| Cranial Technologies, Inc | $33.25 | 2 |
| PFIZER INC. | $33.16 | 2 |
| Acerta Pharma LLC | $22.64 | 1 |
| Astellas Pharma US Inc | $18.69 | 1 |
| Amgen Inc. | $14.83 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2025 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $16.06 | 06/18/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1204645445 | CMS |
| ABBVIE INC. | $21.11 | 06/27/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1204645449 | CMS |
| ABBVIE INC. | $18.78 | 08/13/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1204645453 | CMS |
| Amgen Inc. | $14.83 | 07/08/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1227104338 | CMS |
| Ardelyx, Inc. | $20.66 | 07/01/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1247890649 | CMS |
| Ardelyx, Inc. | $16.63 | 10/02/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1247890651 | CMS |
| Astellas Pharma US Inc | $18.69 | 12/09/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1238619640 | CMS |
| AstraZeneca Pharmaceuticals LP | $22.64 | 06/02/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1207152400 | CMS |
| Cranial Technologies, Inc | $17.30 | 06/03/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1246299186 | CMS |
| Cranial Technologies, Inc | $15.95 | 10/27/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1246312783 | CMS |
| Novo Nordisk Inc | $121.74 | 04/10/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1188143846 | CMS |
| PFIZER INC. | $17.59 | 06/30/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1229047382 | CMS |
| PFIZER INC. | $15.57 | 11/06/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1229955348 | CMS |
| Supernus Pharmaceuticals, Inc. | $14.10 | 05/19/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1244909425 | CMS |
| Supernus Pharmaceuticals, Inc. | $17.25 | 06/25/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1244909429 | CMS |
| Supernus Pharmaceuticals, Inc. | $16.58 | 10/07/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1244909431 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.